AZ signs Adelaide Uni deal
July 3, 2015
University of Adelaide
researchers are being given access
to fifty of global pharma giant
AstraZeneca’s (AZ) drug compounds
to study new therapies in a
groundbreaking new collaboration,
the university has announced.
Adelaide Research and Innovation
(ARI), the University of Adelaide’s
commercialisation arm, sealed the
agreement which is a first for South
Australia.
ARI Deputy Director Dr Jane
Rathjen said the partnership will
“allow for access to optimised
compounds, technologies, multidisciplinary
science, services and
know-how to speed up research
outcomes, and most importantly the
opportunity to see ideas develop
into treatments for patients.”
AstraZeneca and ARI will also fund
successful research proposals that
result from the partnership.
Therapy areas covered include
cardiovascular, metabolic,
respiratory, oncology, autoimmune
& infection and neuroscience,
with AZ to have first rights to
commercialise any discovery made
by the university researchers.
The collaboration is based on
AstraZeneca’s Open Innovation
platfrom, which takes new and
existing compounds out of the
company’s laboratories and into the
hands of research centres.
“Furthering the boundaries of
science is at the core of what
AstraZeneca does, so we’re
absolutely delighted to be
supporting University of Adelaide
researchers who have the potential
to find exciting new developments
in medicine thanks to this
collaboration,” said AZ Australia
president Paul Spittle.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Jul 15To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Jul 15
